Adalimumab News and Research

RSS

Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.

Biosimilars could drive down drug prices and lead to $38.4 billion savings

Biosimilar drugs could drive down prices for expensive medicines used to treat illnesses such as cancer and rheumatoid arthritis, with savings estimated to be $38.4 billion or 5.9% of projected total U.S. spending on biologics from 2021 to 2025, according to a new RAND Corporation study.

10 Jan 2022

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors -; a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions -; generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis.

21 Nov 2021

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Real-world data looking at biologic treatment and vaccine hesitancy in psoriasis patients is being presented today at EADV’s 30th Congress.

1 Oct 2021

Hidradenitis suppurativa: Discontinuation of adalimumab prior to surgery is not necessary

Hidradenitis suppurativa (Syn. Acneinversa) is one of the most troublesome and complicated skin diseases. The anti-inflammatory drug adalimumab can improve symptoms; however, patients also often have to undergo surgery.

19 Aug 2021

Study analyzes uveitis risk after antirheumatic drug withdrawal in children with arthritis

Uveitis is an inflammation of the eye and is a common extra-articular manifestation associated with juvenile idiopathic arthritis (JIA). It can cause vision-threatening complications, and if left uncontrolled may even lead to blindness.

18 Jun 2021

Patient support program for painful conditions may also help avoid use of risky opioids

A program that provides ongoing support to patients with painful conditions and complex medication regimens may also help them avoid using potentially risky opioid pain medications, or reduce the amount they use, a new study finds.

6 May 2021

Shifts in care due to COVID-19 pandemic likely to drive drug expenditures in 2021

The COVID-19 pandemic heavily influenced spending on prescription drugs in the U.S. in 2020, according to the ASHP's (American Society of Health-System Pharmacists) National Trends in Prescription Drug Expenditures and Projections for 2021.

21 Apr 2021

New trial to evaluate anti-TNF drug as a treatment for COVID-19 patients begins

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes.

30 Sep 2020

People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

People suffering from rheumatoid arthritis with increased disease activity are more often affected by thrombosis.

5 Jun 2020

Study focuses on COVID-19 patients with inflammatory rheumatic diseases

The ongoing COVID-19 pandemic has caused nearly five million cases and over 327,000 deaths worldwide. The signs and symptoms of this disease are varied, although there are typical features which assist diagnosis.

20 May 2020

New study to evaluate drug combination treatment for uveitis

Two in 10,000 people are at risk of serious sight loss from a form of eye inflammation known as uveitis. A new clinical research study, led by the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (UHBW), will evaluate a drug combination treatment for the eye disease thanks to funding of £2.5 million by the National Institute for Health Research (NIHR).

13 May 2020

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis (JIA) is a severely undertreated condition, and new medications are badly needed to relieve the signs and symptoms of the illness, according to a new study presented at the 2019 ACR/ARP Annual Meeting.

11 Nov 2019

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis, despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).

10 Nov 2019

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, the live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications.

10 Nov 2019

Work in progress on medicine for treatment of ulcerative colitis

IKBFU center for clinical research scientists have participated in the international VARSITY clinical research. It's the world's first research aimed at finding the most effective drug among anti-inflammatory ones for the treatment of ulcerative colitis.

28 Oct 2019

Study identifies genetic marker which could personalize treatment for Crohn's disease

The largest study ever to look at why an expensive and commonly used group of drugs fails some patients with Crohn's disease has identified a genetic marker which could individualize drug treatment.

7 Oct 2019

Common genetic variant explains why immunotherapy often fails in Crohn's disease

The reason why a commonly used range of immunotherapy drugs is not effective in some patients with Crohn’s disease has so far not been identified, until now.

7 Oct 2019

Two uveitis drugs perform similarly in a head-to-head clinical trial

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S.

11 Sep 2019

Research suggests new way to improve the efficacy of arthritis drug

Attaching a removable lock to an arthritis drug can make it safer and more effective, according to a new study publishing June 13 in the open-access journal PLOS Biology led by Wen-Wei Lin of Kaohsiung Medical University, Taiwan.

From PLOS ONE 14 Jun 2019

Still-to-be-approved drug proves to be new option for treating active rheumatoid arthritis

In a large-scale, international study led by renowned rheumatologist Josef Smolen from the Department of Medicine III, a still-to-be-approved drug containing the selective janus kinase inhibitor upadacitinib has proved itself to be a new option for treating active rheumatoid arthritis.

7 Jun 2019